Matches in Nanopublications for { ?s ?p "[Teprotumumab (RV 001, R1507) is a human monoclonal anti-IGF-1R blocking antibody currently undergoing a phase 2 clinical trial in patients with active TAO.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP481856.RA-jWYMYqMweOfBftB054YL7YU7UE1jC3p7klWN52iAWc130_assertion description "[Teprotumumab (RV 001, R1507) is a human monoclonal anti-IGF-1R blocking antibody currently undergoing a phase 2 clinical trial in patients with active TAO.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP481856.RA-jWYMYqMweOfBftB054YL7YU7UE1jC3p7klWN52iAWc130_provenance.
- NP1186871.RARqUMq1Dt9ulbdyQd6YsWkGOv7ODw_QW-p6ZtynGk_78130_assertion description "[Teprotumumab (RV 001, R1507) is a human monoclonal anti-IGF-1R blocking antibody currently undergoing a phase 2 clinical trial in patients with active TAO.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1186871.RARqUMq1Dt9ulbdyQd6YsWkGOv7ODw_QW-p6ZtynGk_78130_provenance.
- assertion description "[Teprotumumab (RV 001, R1507) is a human monoclonal anti-IGF-1R blocking antibody currently undergoing a phase 2 clinical trial in patients with active TAO.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.